Crystalline forms of cyclohexanone compound
The pharmacokinetics and stability of the compound were solved by preparing the stable crystal form of 3-(15-hydroxypentane)-2,4,4-trimethylcyclohexan-2-en-1-one The problem on the issue has achieved nerve growth stimulation and improvement of urinary function, providing a safe and effective form of drug.
Patent Information
- Application Number
- CN202380032301.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-09
- Filing Date
- 2023-02-08
- Publication Date
- 2024-11-19
AI Technical Summary
The existing 3-(15-hydroxypentane)-2,4,4-trimethylcyclohexan-2-en-1-one performs poorly in pharmacokinetics and lacks stable crystal forms. Difficult to be effective as a nerve growth stimulator and therapeutic agent.
Three stable crystal forms of this compound (type I, type II and type III) were discovered and prepared, which had low hygroscopicity and excellent solid stability, through powder X-ray diffraction patterns and differential scanning calorimetry. Characterization is performed to ensure the chemical and physical stability of the compounds.
It realizes the excellent nerve growth stimulation effect of the compound and improves urinary function, has excellent pharmacokinetic properties, and shows safe low residual solvent levels in drug substances, suitable for the treatment of neurodegenerative diseases and lower urinary tract functions. Drugs for disorders.
Smart Images

Figure BDA0005069340390000021 
Figure BDA0005069340390000181 
Figure BDA0005069340390000211
Abstract
Description
Technical Field
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority based on Japanese Patent Application No. 2022-019058 filed on February 9, 2022, the entire contents of which are incorporated herein by reference. The present disclosure relates to a crystalline form of a cyclohexanone compound that can be used as a pharmaceutical raw material and a pharmaceutical composition comprising the crystalline form. Background Art
[0003] Neurodegenerative diseases are roughly divided into central and peripheral diseases according to the location of damaged nerves. Representative diseases of the central nervous system include Alzheimer's disease, amyotrophic lateral sclerosis and cerebral spinal cord injury. Representative diseases involving peripheral nerve damage include sensory neuropathy, such as neuropathic pain and dysesthesia, and autonomic neuropathy accompanied by constipation or dysuria. Although the pathological mechanisms of neurodegenerative diseases are diverse, these diseases are believed to involve degeneration or atrophy of neurites and / or neuronal cell death. For the above diseases, there is currently a lack of basic therapeutic drugs to improve neuropathy.
[0004] PTL1 discloses that 3-(15-hydroxypentadecanyl)-2,4,4-trimethylcyclohex-2-ene-1-one has a nerve growth stimulating effect and can be used as a drug for preventing or treating brain diseases such as dementia. PTL2 discloses that the compound can be used as a therapeutic agent for dysuria. However, when conventionally prescribed, 3-(15-hydroxypentadecanyl)-2,4,4-trimethylcyclohex-2-ene-1-one performs poorly in terms of pharmacokinetics (PTL3).
[0005] Generally, when a compound is used as an active ingredient or a raw material of a drug, it is required to have chemical and physical stability in order to stably maintain the quality and / or simplify storage management.
[0006] Reference List
[0007] Patent Literature
[0008] PTL1: WO99 / 08987
[0009] PTL2: WO2002 / 066024
[0010] PTL3: WO2013 / 147072 Summary of the invention
[0011] Technical issues
[0012] The object of the present disclosure is to provide a novel compound having excellent neurite outgrowth effect. Another object of the present disclosure is to provide a stable crystalline form of a novel compound that can be used as an active ingredient or bulk drug of a pharmaceutical.
[0013] Solution to the problem
[0014] The inventors of the present application have conducted extensive research to achieve this purpose and have found that a novel cyclohexanone compound represented by the following formula (I) (chemical name: 3-(15-hydroxypentadecanyl)-2,4,4-trimethylcyclohex-2-ene-1-one (hereinafter sometimes referred to as "compound (I)"))
[0015]
[0016] It has a nerve growth stimulating effect (neurite growth effect and / or an effect of increasing the proportion of cells with neurites), and can be used as a drug for treating diseases (including neurodegenerative diseases), pain and / or lower urinary tract dysfunction that are improved by promoting nerve growth. The inventors of the present application also found that compound (I) has three crystal forms (type I crystal, type II crystal and type III crystal), and these crystal forms have low hygroscopicity and excellent solid stability.
[0017] Specifically, the present disclosure provides the following [1] to
[15] .
[0018] [1] A crystalline form of 3-(15-methoxypentadecanyl)-2,4,4-trimethylcyclohex-2-en-1-one, wherein the crystalline form has at least three peaks at diffraction angles (2θ±0.2°) selected from 7.0°, 14.0°, 17.5°, 19.5°, 21.0°, 23.7° and 24.8° in a powder X-ray diffraction pattern (CuKα).
[0019] [2] The crystal form according to [1], wherein the crystal form has peaks at diffraction angles (2θ±0.2°) of 7.0°, 14.0°, 17.5°, 19.5°, 21.0°, 23.7° and 24.8° in a powder X-ray diffraction pattern (CuKα).
[0020] [3] The crystalline form according to [1] or [2], wherein the powder X-ray diffraction pattern is substantially the same as Figure 1 The spectra shown are identical.
[0021] [4] The crystalline form according to any one of [1] to [3], wherein the crystalline form has an endothermic peak with a peak temperature of about 35° C. in differential scanning calorimetry (DSC measurement).
[0022] [5] A pharmaceutical composition comprising the crystal form described in any one of [1] to [4].
[0023] [6] A crystalline form of 3-(15-methoxypentadecanyl)-2,4,4-trimethylcyclohex-2-en-1-one, which has at least five peaks at diffraction angles (2θ±0.2°) selected from 6.1°, 11.4°, 12.5°, 15.1°, 19.4° and 24.0° in a powder X-ray diffraction pattern (CuKα).
[0024] [7] The crystal form according to [6], wherein the crystal form has peaks at diffraction angles (2θ±0.2°) of 6.1°, 11.4°, 12.5°, 15.1°, 19.4° and 24.0° in a powder X-ray diffraction pattern (CuKα).
[0025] [8] The crystalline form according to [6] or [7], wherein the powder X-ray diffraction pattern is substantially the same as Figure 3 The spectra shown are identical.
[0026] [9] The crystalline form according to any one of [6] to [8], wherein the crystalline form has an endothermic peak with a peak temperature (highest peak value) of about 34° C. in differential scanning calorimetry (DSC measurement).
[0027]
[10] A pharmaceutical composition comprising the crystal form described in any one of [6] to [9].
[0028]
[11] A crystalline form of 3-(15-hydroxypentadecanyl)-2,4,4-trimethylcyclohex-2-en-1-one, wherein the crystalline form has at least five peaks at diffraction angles (2θ±0.2°) selected from 11.2°, 12.4°, 14.1°, 14.9°, 18.8° and 19.4° in a powder X-ray diffraction pattern (CuKα).
[0029]
[12] The crystal form according to
[11] , wherein the crystal form has peaks at diffraction angles (2θ±0.2°) of 11.2°, 12.4°, 14.1°, 14.9°, 18.8° and 19.4° in a powder X-ray diffraction pattern (CuKα).
[0030]
[13] The crystalline form according to
[11] or
[12] , wherein the powder X-ray diffraction pattern is substantially the same as Figure 5 The spectra shown are identical.
[0031]
[14] The crystalline form according to any one of
[11] to
[13] , wherein the crystalline form has an endothermic peak with a peak temperature (highest peak value) of about 34° C. in differential scanning calorimetry (DSC measurement).
[0032]
[15] A pharmaceutical composition comprising the crystalline form described in any one of
[11] to
[14] .
[0033] Advantageous Effects of the Invention
[0034] The present disclosure provides the above-mentioned compound (I), which can be used as a compound with a nerve growth stimulating effect. The present disclosure also provides the above-mentioned compound (I), which can be used as a compound with excellent pharmacokinetics and / or improving urinary function. The compound (I) disclosed in the present disclosure is a new compound. Its crystal form, the stable crystal form of compound (I) and its production method are currently unknown. In the present disclosure, the crystal form (type I crystal, type II crystal and type III crystal) of compound (I) is superior to other crystal forms in some aspects, such as handling performance (low hygroscopicity) and / or quality control, and is therefore useful when the compound is used as a bulk drug for a drug.
[0035] Furthermore, the Type I crystal, Type II crystal, and Type III crystal of the present disclosure are safe as pharmaceuticals because the residual solvents are lower than the standard values specified in the Guidelines for Residual Solvents in Pharmaceuticals in the ICH Guidelines. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 : Powder X-ray diffraction pattern (CuKα) of type I crystal of compound (I) obtained in Example 1 (the vertical axis represents intensity (counts), and the horizontal axis represents diffraction angle (2θ)).
[0037] Figure 2 : Differential scanning calorimetry (DSC measurement) curve of type I crystal of compound (I) obtained in Example 1.
[0038] Figure 3 : Powder X-ray diffraction pattern (CuKα) of type II crystal of compound (I) obtained in Example 2 (the vertical axis represents intensity (counts), and the horizontal axis represents diffraction angle (2θ)).
[0039] Figure 4 : Differential scanning calorimetry (DSC measurement) curve of type II crystal of compound (I) obtained in Example 2.
[0040] Figure 5 : Powder X-ray diffraction pattern (CuKα) of the type III crystal of compound (I) obtained in Example 3 (the vertical axis represents intensity (counts), and the horizontal axis represents diffraction angle (2θ)).
[0041] Figure 6 : Differential scanning calorimetry (DSC measurement) curve of type III crystal of compound (I) obtained in Example 3.
[0042] Figure 7 : Moisture absorption / desorption isotherm of type I crystal of compound (I) obtained in Example 1.
[0043] Figure 8 : Moisture absorption / desorption isotherm of type II crystal of compound (I) obtained in Example 2.
[0044] Fig. 9 : Moisture absorption / desorption isotherm of type III crystal of compound (I) obtained in Example 3.
[0045] Fig.10 : Graph of residual urine volume in each group. Values represent mean ± SE. The number n of each group is 10, 10, 12, and 12 from left to right.
[0046] *: p<0.05, significant difference compared with vehicle in Dunnett's test NS: no significant difference compared with vehicle in Dunnett's test
[0047] #: p<0.05, significant difference compared with compound (I) in Student's t test
[0048] ##: p<0.01, significant difference compared with the solvent in Student's t test DETAILED DESCRIPTION
[0049] In this specification, singular forms (such as one, an and this) include both singular and plural forms, unless otherwise specified herein or clearly contradicted by the context. Unless otherwise specified, the term "compound (I)" simply mentioned in this specification refers to "3-(15-hydroxypentadecanyl)-2,4,4-trimethylcyclohex-2-ene-1-one", and is used to refer to both "amorphous form" and "crystal".
[0050] For example, compound (I) can be synthesized according to the method described in Synthesis Example 1 below; but it is not limited to this method.
[0051] In this specification, the terms "crystal" and "amorphous" are used with their usual meanings in the field of pharmaceutical technology to which the present disclosure belongs. In this specification, the term "crystal" and related terms used in this specification can be used interchangeably, such as "crystal form" and "crystal morphology". In addition, the term "amorphous" and related terms used in this specification, such as "amorphous" and "non-crystalline form", can be used interchangeably.
[0052] The crystals of the present disclosure can be separated and purified by known separation and purification techniques, such as recrystallization, crystallization, distillation and column chromatography.
[0053] In this document, unless otherwise specified, the term "crystalline" and related terms used in this specification to refer to a compound, substance, modification, material, component or product means that the compound, substance, modification, material, component or product is substantially crystalline as determined by X-ray diffraction. For example, reference is made to Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams and Wilkins, Baltimore, MD (2005) and The US Pharmacopeia, 23rd edition, 1843-1844 (1995).
[0054] In this document, unless otherwise indicated, the term "crystal form" and related terms in this specification refer to the solid form of the crystal. Crystalline forms include single-component crystal forms and multi-component crystal forms, which may optionally, but as a limitation, include cocrystals, salts (including pharmaceutically acceptable salts), polymorphic forms, solvates, hydrates and / or other molecular complexes. In a specific embodiment, the crystal form of the substance may be substantially free of amorphous forms and / or other crystal forms. In a specific embodiment, the crystal form of the substance may contain less than about 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 20%, 25%, 30%, 35%, 40%, 45% or 50% by weight of one or more amorphous forms and / or other crystal forms.
[0055] The term "co-crystal" refers to a molecular complex derived from a variety of co-crystal forming substances known in the art. Unlike salts, co-crystals generally do not involve hydrogen ion transfer between the co-crystal forming substance and the drug. Instead, they involve intermolecular interactions such as hydrogen bonding, aromatic ring stacking or dispersion forces between the co-crystal forming substance and Compound (I) in the crystal structure.
[0056] As used herein, unless otherwise indicated, the terms "polymorph" and "polymorphic form" and related terms in this specification refer to two or more crystal forms that are essentially composed of the same molecule, molecular group and / or ion. Similar to different crystal forms, different polymorphs also have different physical properties, such as melting point, melting enthalpy, solubility, dissolution characteristics and / or vibrational spectra (a result of the arrangement or conformation of molecules and / or ions in the crystal lattice). Differences in physical properties can affect drug parameters such as storage stability, compressibility and density (which are important in the formulation and manufacture of products) and dissolution rate (which is an important factor in bioavailability). Stability differences can be caused by changes caused by chemical reactivity (for example, oxidation differences cause a dosage form composed of one polymorph to undergo color changes faster than a dosage form composed of another polymorph), or by mechanical changes (for example, when a kinetically favorable polymorph is converted to a thermodynamically more stable polymorph, the tablet will disintegrate during storage), or by both (for example, tablets of some polymorphs are more easily degraded under high humidity). As a result of differences in solubility / dissolution properties, solid state transitions can partially lead to loss of efficacy in some extreme cases, and can lead to toxicity in other extreme cases. In addition, physical properties are important during processing (e.g., some polymorphs can form solvates relatively easily, or may not be easily filtered or washed to remove impurities; also, particle shape and size distribution can differ among polymorphs.).
[0057] As used herein, unless otherwise indicated, the terms "amorphous" and "non-crystalline form" and related terms used in this specification mean that the substance, composition or product is substantially non-crystalline as determined by X-ray diffraction. In particular, the term "non-crystalline form" describes an irregular solid form, i.e., a solid form lacking long-range lattice order.
[0058] The term "pharmaceutically acceptable salt" refers to salts derived from various organic and inorganic counterions known in the art. Pharmaceutically acceptable salts are safe for animal or human ingestion.
[0059] Techniques for characterizing crystalline and amorphous forms include, but are not limited to, thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), single crystal X-ray diffraction, vibrational spectroscopy such as infrared (IR) and Raman spectroscopy, solid state and solution nuclear magnetic resonance (NMR) spectroscopy, optical microscopy, hot stage optical microscopy, scanning electron microscopy (SEM), electron crystallography and quantitative analysis, particle size analysis, surface area analysis, solubility measurements, dissolution measurements, atomic analysis, and Karl Fischer analysis. Characteristic crystal cell parameters can be determined by one or more techniques, such as, but not limited to, X-ray diffraction and neutron diffraction, including single crystal diffraction and powder diffraction. Techniques that can be used to analyze powder diffraction data include profile refinement, such as Rietveld refinement, which can be used, for example, to analyze diffraction peaks associated with a single phase in a sample containing two or more solid phases. Other methods that can be used to analyze powder diffraction data include unit cell indexing, which allows one skilled in the art to determine unit cell parameters from a sample containing crystalline powder.
[0060] In powder X-ray diffraction patterns, due to the nature of the data, the diffraction angles and the overall pattern are important in identifying the identity of the crystals. The relative intensities in a powder X-ray diffraction pattern may vary slightly depending on crystal growth direction, particle size, measurement conditions, etc., and should not be interpreted strictly.
[0061] The values obtained in different patterns may have slight errors depending on the crystal growth direction, particle size, measurement conditions, etc. Therefore, in this specification, the diffraction angle (2θ) values in the powder X-ray diffraction pattern may have a measurement error within the range of about ±0.2°.
[0062] For an endothermic peak in a differential scanning calorimetry (DSC measurement) curve, the measurement temperature may differ depending on the rate of temperature increase per minute, sample purity, etc. In this specification, the term "approximately" for a measured temperature value in DSC means that the temperature value is within ±2°C, ±3°C, ±4°C, or ±5°C of the value.
[0063] In one embodiment of the present disclosure, the type I crystal of compound (I) exhibits, for example Figure 1 The powder X-ray diffraction pattern (CuKα) shown in FIG. Figure 2 Differential Scanning Calorimetry (DSC measurement) curve shown.
[0064] In the powder X-ray diffraction pattern (CuKα) of type I crystal of compound (I), characteristic peaks can be observed at diffraction angles (2θ±0.2°) of 7.0°, 14.0°, 17.5°, 19.5°, 21.0°, 23.7° and 24.8°.
[0065] The type I crystal of compound (I) of the present disclosure is a crystal form having at least three peaks selected from the above peaks, preferably at least five peaks selected from the above peaks, and particularly preferably all of the above peaks.
[0066] In the differential scanning calorimetry (DSC measurement) curve of type I crystal of compound (I), an endothermic peak can be observed, for example, at about 33°C to 37°C, preferably about 34°C to 36°C, more preferably about 35°C.
[0067] The crystal morphology according to the present disclosure can be characterized by a combination of the above non-contradictory embodiments. For example, the crystal morphology can be characterized by a combination of peaks in an X-ray diffraction pattern and endothermic peaks measured by DSC.
[0068] In one embodiment, the crystal form disclosed in this specification may include multiple crystals (crystalline polymorphs) with regular spatial arrangement of atoms, and may give different physicochemical properties. In one embodiment, the crystal form disclosed in this specification may be a mixture including crystalline polymorphs.
[0069] In one embodiment, the crystalline form of compound (I) disclosed in this specification can be physically and / or chemically pure. In a specific embodiment, the crystalline form of compound disclosed in this specification can have at least about 100%, 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% physical / chemical purity. In one embodiment, the crystalline form of compound (I) disclosed in this specification is substantially pure. As used herein, unless otherwise indicated, a "substantially pure" sample is, for example, a sample that contains a particular crystalline form or amorphous form and is substantially free of other solid forms and / or other compounds, and in specific embodiments, contains less than about 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.75%, 0.5%, 0.25% or 0.1% by weight of one or more other solid forms and / or other compounds.
[0070] In one embodiment, the crystalline form of compound (I) disclosed in this specification is stable after exposure to about 1, 2, 3, 4, 5, 6, 7, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 or 156 weeks or more, and about 160, 156, 150, 138, 126, 114, 102, 90, 78, 66, 54, 42, 30, 24, 18, 12 or 6 weeks or less at about 25°C, 30°C or 35°C and about 65%, 70%, 75%, 80% or 85% relative humidity. The conditions can be closed or open conditions. In this article, "closed" conditions refer to that the lid of the bottle containing the sample is closed or sealed during the stability experiment, while "open" conditions refer to that the lid is open. In an embodiment, the crystal form of compound (I) disclosed in this specification is stable after exposure to about 25°C and 60% relative humidity for 4 weeks. In one embodiment, the conditions are closed conditions. That is, the crystal form of the compound disclosed in this specification has good storage stability for a long time. In this specification, "stable" means that the increase in the amount of impurities does not exceed about 1.0%, 0.5%, 0.3%, 0.1%, 0.05% or 0.01% compared to the original amount of impurities.
[0071] Stability can also be demonstrated, for example, by retaining 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% or more of the original peak at (2θ ± 0.2°) in an X-ray diffraction pattern.
[0072] The crystal forms of the present disclosure may be solvates (eg, hydrates) or unsolvates.
[0073] The compounds of the present specification or pharmaceutically acceptable salts thereof also include compounds labeled with isotopes (such as deuterium, 3H, 14C, 35S and 125I).
[0074] In one embodiment of the present disclosure, the type I crystal of compound (I) can be obtained by, for example, a method comprising the following steps: step (i-1) adding compound (I) to solvent I-1 to dissolve; and step (i-2) adding solvent I-2 to the solution of compound (I) obtained in step (i-1), and then stirring to crystallize compound (I). In this embodiment, examples of solvent I-1 include methanol, ethanol, 1-propanol, 2-propanol and acetone.
[0075] In step (i-1), the amount of compound (I) added is not particularly limited. For example, compound (I) can be added in an amount of 0.1 to 20 g, preferably 0.5 to 5 g per 10 mL of solvent I-1 on a mass basis. The temperature in step (i-1) is appropriately set according to the solvent used, and is set between 20° C. and the boiling point of the solvent.
[0076] In the above embodiment, solvent I-2 can be, for example, water. The ratio of solvent I-1 to solvent I-2 (v / v) can be, for example, 0 to 50 ml, preferably 0 to 20 ml, of solvent I-2 per 10 mL of solvent I-1. The crystallization temperature in step (i-2) is appropriately set according to the solvent used, and is set between -20°C and 30°C.
[0077] Compound (I) can also be crystallized by adding solvent I-1 and solvent I-2 simultaneously, heating the mixture to dissolve, and then stirring and cooling.
[0078] The stirring crystallization in step (i-2) is appropriately performed using a stirrer, a stirring blade, a magnetic stirrer, etc., depending on, for example, the amount of the solvent and the size of the reaction vessel. The stirring speed is usually 1 to 1200 rpm, preferably 10 to 600 rpm.
[0079] The type I crystal obtained as described above has a chemical purity of compound (I) of 90% or more, which can be measured by high performance liquid chromatography (HPLC). The type I crystal preferably has a chemical purity of compound (I) of 95% or more, more preferably 99% or more.
[0080] The type I crystal of compound (I) including the type I crystal may be a single crystal of the type I crystal or may be a polycrystalline mixture further including other crystals. The type I crystal of compound (I) preferably includes 90 wt % or more, more preferably 95 wt % or more of the type I crystal.
[0081] In one embodiment of the present disclosure, the type II crystal of compound (I) exhibits, for example Figure 3 The powder X-ray diffraction pattern (CuKα) shown in FIG. Figure 4 Differential Scanning Calorimetry (DSC measurement) curve shown.
[0082] In the powder X-ray diffraction pattern (CuKα) of type II crystal of compound (I), characteristic peaks can be observed at diffraction angles (2θ±0.2°) of 6.1°, 11.4°, 12.5°, 15.1°, 19.4° and 24.0°.
[0083] The type II crystal of compound (I) of the present disclosure is a crystal having at least five peaks selected from the above-mentioned peaks, and particularly preferably having all of the above-mentioned peaks.
[0084] In the differential scanning calorimetry (DSC measurement) curve of type II crystal of compound (I), an endothermic peak can be observed, for example, at about 32 to 36°C, preferably about 33 to 35°C, more preferably about 34°C.
[0085] In one embodiment of the present disclosure, type II crystals of compound (I) can be obtained by, for example, a method comprising the following steps: step (ii-1) adding compound (I) to solvent II to dissolve; and step (ii-2) cooling the solution of compound (I) obtained in step (ii-1) to crystallize compound (I). In this embodiment, solvent II can be, for example, acetonitrile.
[0086] In step (ii-1), the amount of compound (I) added is not particularly limited. For example, compound (I) can be added in an amount of 1 to 4 g, preferably 1.5 to 3.5 g per 10 mL of solvent III on a mass basis. The temperature in step (ii-1) is appropriately set according to the solvent used, and it is set between 15 ° C and 40 ° C. The crystallization temperature in step (ii-2) is set between -10 ° C and 5 ° C. Preferably, the temperature is cooled from the temperature in step (ii-1) to a temperature below 3 ° C, and then maintained at a temperature below 3 ° C.
[0087] The crystallization in step (ii-2) can be carried out by stirring. In this case, according to, for example, the amount of the solvent and the size of the reaction vessel, stirring is appropriately carried out using a stirrer, a stirring blade, etc. The stirring operation can also be carried out by, for example, shaking the reaction vessel. The stirring speed is generally 1 to 600 rpm, preferably 10 to 100 rpm.
[0088] The type II crystal obtained as described above has a chemical purity of 90% or more of compound (I), which can be measured by high performance liquid chromatography (HPLC). The type II crystal preferably has a chemical purity of 95% or more, more preferably 99% or more of compound (I).
[0089] The type II crystal of compound (I) including the type II crystal may be a single crystal of the type II crystal, or may be a polycrystalline mixture further including other crystals. The type II crystal of compound (I) preferably includes 90 wt % or more, more preferably 95 wt % or more of the type II crystal.
[0090] In one embodiment of the present disclosure, the type III crystal of compound (I) exhibits, for example Figure 5 The powder X-ray diffraction pattern (CuKα) shown in FIG. Figure 6 Differential Scanning Calorimetry (DSC measurement) curve shown.
[0091] In the powder X-ray diffraction pattern (CuKα) of type III crystal of compound (I), characteristic peaks can be observed at diffraction angles (2θ±0.2°) of 11.2°, 12.4°, 14.1°, 14.9°, 18.8° and 19.4°.
[0092] The type III crystal of compound (I) of the present disclosure is a crystal having at least five peaks selected from the above-mentioned peaks, and particularly preferably having all of the above-mentioned peaks.
[0093] In the differential scanning calorimetry (DSC measurement) curve of type III crystal of compound (I), an endothermic peak can be observed, for example, at about 32 to 36°C, preferably about 33 to 35°C, more preferably about 34°C.
[0094] In one embodiment of the present disclosure, type III crystals of compound (I) can be obtained by, for example, a method comprising the following steps: step (iii-1) adding type II crystals of compound (I) to solvent III-1 and stirring the mixture; step (iii-2) recovering the solid of compound (I) from the suspension of compound (I) obtained in the above step (iii-1). In this embodiment, solvent III-1 can be a mixed solvent of methanol and water. When a mixed solvent of methanol and water is used, the ratio (v / v) can be, for example, 1 to 15 ml, preferably 5 to 11 ml of water per 100 ml of methanol.
[0095] In step (iii-1), the amount of type II crystals of compound (I) added is not particularly limited. For example, compound (I) can be added in an amount of 1 to 5 g, preferably 1.5 to 2.5 g per 10 mL of solvent III-1 on a mass basis. The temperature in step (iii-1) is appropriately set according to the solvent used, and is set between 0°C and 8°C.
[0096] The recovery method used in step (iii-2) can be selected from various methods available in the technical field to which the present disclosure belongs, such as filtration, organic solvent washing and vacuum drying.
[0097] The stirring in step (iii-1) is appropriately performed using a stirrer, a stirring blade, a magnetic stirrer, etc., depending on, for example, the amount of the solvent and the size of the reaction solvent. The stirring speed is usually 1 to 600 rpm, preferably 10 to 300 rpm.
[0098] The type III crystal obtained as described above has a chemical purity of 90% or more of compound (I), which can be measured by high performance liquid chromatography (HPLC). The type III crystal preferably has a chemical purity of 95% or more, more preferably 99% or more of compound (I).
[0099] The type III crystal of compound (I) including the type III crystal may be a single crystal of the type III crystal, or may be a polycrystalline mixture including other crystals. The type III crystal of compound (I) preferably includes 90 wt% or more, more preferably 95 wt% or more of the type III crystal.
[0100] As shown in the following examples, the Type I crystal / Type II crystal and Type III crystal of Compound (I) according to the present disclosure have low hygroscopicity and excellent solid-state stability (such as storage stability). Having solid stability in industrial production and maintaining quality is very important for the active ingredients contained in the raw materials of the drug and the drug.
[0101] Solvents used in drug production may be toxic, and from a safety perspective, it is desirable to have as little residual solvent as possible during the manufacturing process. In this regard, Type I crystals, Type II crystals, and Type III crystals of Compound (I) do not contain residual solvents exceeding the limits specified in the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) guidelines.
[0102] Therefore, according to the present disclosure, the type I crystal, type II crystal and type III crystal of compound (I) all have excellent properties required as a pharmaceutical product or a pharmaceutical raw material.
[0103] According to the present disclosure, the type I crystal, type II crystal and type III crystal of compound (I) all have excellent neurite outgrowth effect. For example, due to the neurite outgrowth effect and / or the effect of increasing the proportion of cells with neurites, the type I crystal, type II crystal and type III crystal of compound (I) according to the present disclosure can be used as a drug for treating diseases (including neurodegenerative diseases) improved by promoting nerve growth, pain and / or lower urinary tract dysfunction.
[0104] For the use of type I crystals, type II crystals and / or type III crystals of compound (I) as pharmaceuticals, various dosage forms of type I crystals, type II crystals and / or type III crystals crushed or not crushed can be used according to the purpose of prevention or treatment. Examples of this form include oral drugs, such as tablets, capsules, granules, fine particles, powders and dry syrups; and non-oral drugs, such as suppositories, inhalants, nasal drops, ointments, patches and injections. The form of oral drugs is preferred. These pharmaceutical compositions can be manufactured by using a pharmaceutically acceptable carrier and according to a formulation method known and commonly used by those skilled in the art.
[0105] The pharmaceutical carrier used can be various organic or inorganic carrier substances commonly used as formulation materials. For example, the pharmaceutical carrier is added to a solid preparation as an excipient, binder, disintegrant, lubricant or coating agent, or is added to a liquid preparation as a solvent, solubilizer, suspending agent, isotonic agent, buffer or soothing agent. Additionally, formulation additives such as preservatives, antioxidants, coloring agents, sweeteners and stabilizers can be optionally used.
[0106] Examples of the excipient include lactose, sucrose, D-mannitol, starch, crystalline cellulose and calcium carbonate.
[0107] Examples of the binder include hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, powdered sugar and hydroxypropyl methyl cellulose.
[0108] Examples of disintegrants include sodium starch glycolate, carboxymethylcellulose calcium, croscarmellose sodium, crospovidone, low-substituted hydroxypropyl cellulose, and partially pregelatinized starch.
[0109] Examples of lubricants include talc, magnesium stearate, sucrose fatty acid esters, stearic acid and sodium stearyl fumarate.
[0110] Examples of coating agents include ethylcellulose, aminoalkyl alcohol methacrylate copolymer RS, hydroxypropyl methylcellulose, and sucrose.
[0111] Examples of solvents include water, propylene glycol, and saline solutions.
[0112] Examples of the solubilizing agent include polyethylene glycol, ethanol, α-cyclodextrin, polyethylene glycol 400, and polysorbate 80.
[0113] Examples of the suspending agent include carrageenan, crystalline cellulose-sodium carboxymethylcellulose and hydrogenated castor oil polyoxyethylene esters.
[0114] Examples of isotonic agents include sodium chloride, glycerol, and potassium chloride.
[0115] Examples of pH adjusters and buffers include sodium citrate, hydrochloric acid, lactic acid, phosphoric acid, and sodium dihydrogen phosphate.
[0116] Examples of demulcents include procaine hydrochloride and lidocaine.
[0117] Examples of preservatives include ethylparaben, cresol, and benzalkonium chloride.
[0118] Examples of antioxidants include sodium sulfite, ascorbic acid, and natural vitamin E.
[0119] Examples of the colorant include titanium oxide, ferric oxide, food blue No. 1, and copper chlorophyll.
[0120] Examples of taste- or odor-masking agents include aspartame, saccharin, sucralose, l-menthol, and mint flavors.
[0121] Examples of the stabilizer include sodium metabisulfite, sodium edetate, isoascorbic acid, magnesium oxide, and butylated hydroxytoluene.
[0122] Oral solid preparations can be prepared by the following method: adding excipients and optionally adding binders, disintegrants, lubricants, colorants, taste-masking or odor-masking agents, etc. to Type I crystals, Type II crystals and / or Type III crystals of Compound (I), and formulating the resulting mixture into tablets, coated tablets, granules, powders, capsules or the like by conventional methods.
[0123] The amount of type I crystal, type II crystal and / or type III crystal of compound (I) contained in each unit dosage form is preferably typically about 0.05 to 1000 mg per unit dosage form for oral medication, about 0.1 to 500 mg per unit dosage form for injection, and about 1 to 1000 mg per unit dosage form for suppository or external application, but this amount is not fixed, for example, depending on the symptoms of the patient to be treated or the dosage form.
[0124] Although the daily dose of the Type I crystal, Type II crystal and / or Type III crystal of Compound (I) in the above dosage form cannot be generalized due to the diversity of patient symptoms, body weight, age, sex, etc., for an adult (body weight: 50 kg), the daily dose may generally be about 0.05 to 5000 mg, preferably 0.1 to 1000 mg. This dose of the drug may be administered once a day, or in about two to three divided doses a day.
[0125] Example
[0126] The present disclosure is described in more detail below with reference to examples. However, the present disclosure is not limited to these examples. Although the present disclosure is fully described by examples, it will be appreciated by those skilled in the art that various changes and / or modifications may be provided. Therefore, the present disclosure includes such changes and / or modifications unless they deviate from the essence and main concept of the present disclosure.
[0127] Unless otherwise specified, the reagents used in the examples are all commercially available products. NMR spectra were acquired using an AL400 NMR spectrometer (400 MHz; manufactured by JEOL). When the deuterated solvent contained tetramethylsilane, tetramethylsilane was used as an internal standard. Otherwise, the peak of the non-deuterated protons remaining in the NMR solvent was used as an internal standard for measurement. δ values are all expressed in ppm.
[0128] These symbols represent the following.
[0129] s: Single peak
[0130] t: Three Peaks
[0131] m: multiple peaks
[0132] CDCl3: deuterated chloroform
[0133] Powder X-ray diffraction measurements
[0134] After a proper amount of experimental raw materials were lightly ground in an agate mortar as required, powder X-ray diffraction was measured under any of the following experimental conditions.
[0135] Instrument: Empyrean, manufactured by PANalytical
[0136] Reflection method (focusing method)
[0137] Target material: Cu
[0138] X-ray tube current: 40mA
[0139] X-ray tube voltage: 45kV
[0140] Scanning range: 2θ = 5.0 to 40.0°
[0141] Step size: 2θ = 0.0131°
[0142] Average time / step: 8.670s
[0143] Scanning speed: 0.0015° / s
[0144] Divergence slit: 1°
[0145] Scattering slit: 2.0mm
[0146] Light receiving slit: 8.0mm
[0147] The operation of the instruments, including data processing, shall be carried out according to the methods and procedures indicated on each instrument.
[0148] The values obtained from different spectra may vary slightly depending on factors such as crystal growth direction, particle size, measurement conditions, etc., and should not be interpreted strictly.
[0149] Differential Scanning Calorimetry (DSC Measurement)
[0150] The DSC measurement was performed according to the following experimental conditions.
[0151] Instrument: DSC1 STAR system, manufactured by Mettler Toledo
[0152] Sample: about 1 mg
[0153] Sample container: Aluminum
[0154] Temperature rise range: 25 to 290°C
[0155] Temperature increase rate: 10℃ / min
[0156] Ambient gas: Nitrogen
[0157] Nitrogen flow rate: 50mL / min
[0158] The operation of the instruments, including data processing, shall be carried out according to the methods and procedures indicated on each instrument.
[0159] 3-(15-Hydroxypentadecanyl)-2,4,4-trimethylcyclohex-2-en-1-one described below is also referred to as "Compound A".
[0160] Synthesis Example 1: Synthesis of 3-(15-methoxypentadecanyl)-2,4,4-trimethylcyclohex-2-en-1-one (compound (I))
[0161] A solution of 72.9g 3-(15-hydroxypentadecanyl)-2,4,4-trimethylcyclohex-2-ene-1-one in 150mL tetrahydrofuran was added dropwise to a solution of 48.1g sodium tert-butoxide in 550mL tetrahydrofuran at an ice-cold temperature, and the mixture was stirred for 30 minutes. Then, a solution of 56.8g iodomethane in 50mL tetrahydrofuran was added to the reaction mixture, and stirred for 0.5 hour at an ice-cold temperature, and stirred for 1.5 hours at room temperature. At an ice-cold temperature, a saturated ammonium chloride solution was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate, washed with water and brine, and dried over anhydrous sodium sulfate. After filtering out the desiccant, the residue obtained by evaporation under reduced pressure was purified by silica gel column chromatography (ethyl acetate / ethane) to obtain 61.5g of the title compound.
[0162] Example 1: Preparation of Type I Crystal of Compound (I)
[0163] Methanol (4 mL) and water (3 mL) were added to 1.00 mg of compound (I), and the mixture was heated and stirred. Then, the mixture was cooled to room temperature under stirring. The precipitate was collected by filtration and dried under reduced pressure at room temperature to obtain 892 mg of the title crystal. 1 The H-NMR spectrum is shown below.
[0164] NMR(CDCl3)δppm 1.15(s,6H),1.20-1.48(m,24H),1.50-1.63(m,2H),1.75(s,3H),1.75-1.85(m,2 H),2.13-2.24(m,2H),2.45(t,J=6.8Hz,2H),3.33(s,3H),3.36(t,J=6.8Hz,2H).
[0165] Figure 1A powder X-ray diffraction pattern (CuKα) is shown.
[0166] The characteristic diffraction angles are as follows. Characteristic diffraction angles (2θ±0.2°): 7.0°, 14.0°, 17.5°, 19.5°, 21.0°, 23.7° and 24.8° (CuKα)
[0167] The results of differential scanning calorimetry (DSC) of the type I crystal are as follows.
[0168] Differential scanning calorimetry curve: Figure 2 Shown
[0169] Differential scanning calorimetry curve endothermic peak (peak): around 35°C
[0170] Example 2: Preparation of Type II Crystals of Compound (I)
[0171] Acetonitrile (4 mL) was added to 1000 mg of compound (I) to dissolve it. The resulting product was cooled on ice, and the precipitate was collected by filtration, and the solid was recovered and dried under reduced pressure at room temperature for about 45 minutes to obtain 747.0 mg of the title crystal.
[0172] Figure 3 A powder X-ray diffraction pattern (CuKα) is shown.
[0173] The characteristic diffraction angles are as follows: Characteristic diffraction angles (2θ±0.2°): 6.1°, 11.4°, 12.5°, 15.1°, 19.4° and 24.0° (CuKα).
[0174] The results of differential scanning calorimetry (DSC) of the type II crystal are as follows.
[0175] Differential scanning calorimetry curve: Figure 4 Shown
[0176] Differential scanning calorimetry curve endothermic peak (peak): around 34°C
[0177] Example 3: Preparation of Type III Crystals of Compound (I)
[0178] 3.25 mL of a liquid mixture of methanol / water (9:1 v / v) was added to 650 mg of the Type II crystals of compound (I) obtained in Example 2, and the suspension was stirred at 4 ° C for about 100 minutes. It was then filtered, the solid was recovered and dried under reduced pressure at room temperature for about 25 minutes. A 2.5 mL amount of a liquid mixture of methanol / water (9:1 v / v) was added to 500 mg of the solid, and the suspension was stirred at 4 ° C for about 19 hours. It was then filtered, the solid was recovered and dried under reduced pressure at room temperature for about 25 minutes to obtain 335.6 mg of the title crystal.
[0179] Figure 5A powder X-ray diffraction pattern (CuKα) is shown.
[0180] The characteristic diffraction angles are as follows: Characteristic diffraction angles (2θ±0.2°): 11.2°, 12.4°, 14.1°, 14.9°, 18.8° and 19.4°.
[0181] The results of differential scanning calorimetry (DSC) of the type III crystal are as follows.
[0182] Differential scanning calorimetry curve: Figure 6 Shown
[0183] Differential scanning calorimetry curve endothermic peak (peak): around 34°C
[0184] Test Example 1: Solid Stability Test
[0185] The type I crystal, type II crystal and type III crystal of Compound (I) obtained in Examples 1 to 3 were evaluated for solid stability after storage for 4 weeks.
[0186] Storage conditions: 25℃ / 60% RH (closed system)
[0187] Storage period: 4 weeks
[0188] Storage capacity: about 25mg
[0189] Storage container: glass bottle
[0190] About 1 mg of sample was weighed and dissolved in 2 mL of acetonitrile, 5 μL of the liquid was accurately measured and subjected to HPLC analysis according to the following method to analyze the change in the purity of compound (I) and the amount of related substances (the amount of substances detected other than compound (I)). The operation of the instrument, including data processing, was carried out according to the methods and steps indicated by each instrument.
[0191] Column: YMC-Triart C8 (4.6×150 mm, 3 μm), manufactured by YMC Co., Ltd. UV detection: 248 nm
[0192] Column temperature: 40°C
[0193] Flow rate: 1mL / min
[0194] Sample cooler: 25°C
[0195] Sample concentration: 0.5 mg / mL
[0196] Mobile phase A: a liquid mixture of water / acetonitrile (1:1 v / v)
[0197] Mobile phase B: acetonitrile
[0198] The gradients are shown in Table 1.
[0199] Table 1
[0200] Time (min) Mobile phase A (volume %) Mobile phase B (volume %) 0 47 53 16 0 100 30 0 100 31 47 53 40 47 53
[0201] The results are shown in Table 2 below.
[0202] Table 2
[0203]
[0204] As shown in Table 2, the purity of type I crystal, type II crystal and type III crystal of compound (I) is almost unchanged. In addition, type I crystal, type II crystal and type III crystal of compound (I) have almost no increase in related substances. These results show that type I crystal, type II crystal and type III crystal of compound (I) are extremely stable crystals.
[0205] Test Example 2: Dynamic Moisture Adsorption / Desorption Test
[0206] After storage for 4 weeks, the type I crystal, type II crystal and type III crystal of compound (I) obtained in Examples 1 to 3 were subjected to a moisture adsorption / desorption test.
[0207] The moisture sorption / desorption test was carried out under the following conditions.
[0208] About 10 mg of sample was placed in a dedicated quartz container, and the weight of the sample at each humidity was continuously measured and recorded under the following conditions. The operation of the instrument, including data processing, was carried out according to the methods and steps indicated by each instrument.
[0209] Instrument: VTI-SA+ (TA Instruments, Inc)
[0210] Drying temperature: 25℃
[0211] Temperature increase rate: 1℃ / min
[0212] Drying balance: within a range of not more than 120 minutes, confirm that there is no reduction of 0.01 wt% within 5 minutes.
[0213] Measurement temperature: 25℃
[0214] Wet balance: within a range of not more than 120 minutes, confirm that there is no increase of 0.01 wt% within 5 minutes.
[0215] Relative humidity program: increase by 5% RH, increase from 5% RH to 95% RH, decrease by 5% RH, decrease from 95% RH to 5% RH
[0216] The weight variations within the range of measurement conditions obtained in these tests are as follows Figures 7 to 9 shown.
[0217] like Figures 7 to 9 As shown, type I crystal, type II crystal and type III crystal of compound (I) hardly absorb moisture at a relative humidity of 95% in a moisture adsorption / desorption test.
[0218] Therefore, the type I crystal, type II crystal and type III crystal of compound (I) have low hygroscopicity and are considered to be superior in industrial production of pharmaceutical products with stable quality in the development of candidate compounds for pharmaceutical products.
[0219] Type I crystals, Type II crystals and Type III crystals of Compound (I) have high stability as described above. A pharmaceutical suspension or pharmaceutical solution of Compound (I) can be prepared by adding these crystals to water together with an amphiphilic compound such as hydroxypropylmethylcellulose or dimethyl sulfoxide (DMSO).
[0220] Test Example 3: Pharmacokinetics
[0221] The required amount of compound (I) was weighed and a drug suspension was prepared in 0.5% hydroxypropylmethylcellulose. Each group of two rats was administered each drug suspension (the dose of the compound was 10 mg / kg) by oral sonde to each male rat (Crl: CD (SD)). At each blood sampling point (0.5, 1, 2, 4, 8 and 24 hours after administration), blood was collected from the jugular vein using a syringe and needle (the anticoagulant was sodium heparin). The collected blood was centrifuged (13000 rpm, 2 min, 4°C) to prepare plasma, which was then deproteinized. Then, the concentration of the compound in plasma was detected by LC / MS / MS (LCMS-8040 (Shimadzu Corporation)) or API 4000 (AB Sciex), LC: 30-A and 20-A series (Shimadzu Corporation) or Waters Acquity (Waters Corporation). Compound A was used instead of compound (I), and the drug suspension was prepared and administered in the same manner as above, and the concentration of the compound was tested. The results are shown in Table 3.
[0222] As shown in Table 3, it was confirmed that the area under the curve (AUC) of compound (I) was increased by 1900 times or more compared with compound A, and the maximum blood concentration C max The improvement was 1100 times or more. Therefore, the results showed that compound (I) has unexpectedly high pharmacokinetic levels compared to the known compound A.
[0223] Table 3 AUC and C of each compound max
[0224] <![CDATA[AUC 0-∞ ]]> <![CDATA[C max (μM)]]> Compound A 0.003 0.002 Compound (I) 5.90 2.20
[0225] Test Example 4: Evaluation of drug efficacy in diabetic (DM) rat model
[0226] To investigate the effect of the compound on the diabetic model, bladder function was analyzed based on the cystometry method of Saitoh et al. (European Journal of Pharmacology 501 (2004) 143-149).
[0227] The STZ solution was prepared by dissolving streptozotocin (STZ) in citrate buffer (0.1 M citric acid, pH 4.2) to a concentration of 32.5 mg / mL and intraperitoneally administered (65 mg / kg) to SD rats to induce the DM model. The same operation was performed on sham-operated rats, except that the STZ solution was replaced with citrate buffer.
[0228] The next day after modeling and 4 weeks later, blood samples were taken from the tail vein of the rats when they were awake to detect blood glucose levels. AntSense III (Horiba Corporation) was used to detect blood glucose levels. The next day after modeling and 4 weeks later, individuals with blood glucose levels of 300 mg / dL or higher were determined to have established a DM model and were used for subsequent operations.
[0229] The administration of the test substance (Compound A or Compound (I)) starts the next day after modeling. The vehicle or the solution for administering the compound is administered twice a day, morning and evening, with a volume of 10mL / kg for 4 weeks. The next day after the last administration of the test drug, an incision is made in the abdomen of each rat under isoflurane anesthesia, and a catheter (PE-90, Becton Dickinson and Company) is inserted through the bladder tip to measure the intravesical pressure. After closing the abdomen, the rat is placed in a cage. After releasing isoflurane anesthesia for at least 30 minutes, urethane solution (0.8g / kg) is administered subcutaneously.
[0230] A pressure sensor (DX-360, Nihon Kohden Kogyo Co., Ltd.) and an infusion pump (TE-331S, Terumo Corporation) were connected to the other end of the catheter inserted into the bladder through a three-way valve. The intravesical pressure during continuous intravesical infusion of saline (infusion rate: 12 mL / hr) was measured using a pressure sensor and a multichannel physiological recorder (AP-641G, Nihon Kohden Kogyo Co., Ltd.) and continuously recorded on a computer using PowerLab (ML866, AD Instruments) (sampling rate: 20 / sec). The amount of urine was automatically measured using an electronic balance (GX-200, A&D Company Limited) set just below the cage and continuously recorded on a computer using PowerLab (sampling rate: 20 / sec). PowerLab analysis software Chart5 (ver.5.5.6, AD Instruments) was used to record and analyze urinary function parameters.
[0231] Immediately after isoflurane anesthesia, a 1.5-hour continuous intravesical infusion of normal saline was performed to familiarize the rats with the cystometry environment. After adaptation to the cystometry environment, urinary function (intravesical bladder pressure, urine output, and residual urine volume) was measured using cystometry (infusion rate: 12 mL / hour).
[0232] like Fig.10 As shown, it was found that compound (I) has significant pharmacological efficacy compared to compound A.
[0233] Test Example 5: Detection of nerve growth stimulation effect
[0234] In order to evaluate the nerve growth stimulating effect, neurite outgrowth detection (proportion of cells carrying neurites) and neurite length detection (neurite length) were performed with reference to the method of Topalli et al. (Brain Research 1030 (2004), pp. 116-124).
[0235] ND3 neuronal cell line (European Collection of Authenticated Cell Cultures) was seeded in DMEM medium containing 10% fetal bovine serum (0.6×10 4Cells / 1mL) and placed in a 24-well plate. After 24 hours, the culture medium inoculated with cells was removed, and a solution of compound (I) serially diluted in dimethyl sulfoxide (DMSO) was added to DMEM containing 0.1% fetal bovine serum so that the final concentration of DMSO was 0.1%, and the solution was added to the cells (repeated twice for evaluation). After 6 hours of addition, the proportion of cells carrying neurites (the number of cells with neurites longer than the diameter of the cell body / total number of cells) and the length of neurites per cell were analyzed. In addition, compound A was used to replace compound (I) and the same method as above was used for detection. MetaMorph Neurite Outgrowth Application Module (Molecular Devices Japan KK) was used to analyze the total cell number, the proportion of cells carrying neurites, and the length of neurites per cell. The number of cells is defined as the relative number of cells, and the number of cells per well containing DMSO is set to 1 (Tables 4 and 5). Table 5 shows the relative activity of compound A when the maximum activity of 3-(15-methoxypentadecanyl)-2,4,4-trimethylcyclohex-2-ene-1-one (compound (I)) in each experiment is defined as 1. Multiple experiments were performed and the average value is shown. Data when the number of cells was 0.5 or more were used. Therefore, if the number of cells was less than 0.5, the neurite length per cell and the ratio of neurite cells were defined as "-".
[0236] As shown in Table 4, when compound (I) was added in an amount of 1 to 100 μM, the relative cell number was 0.5 or more.
[0237] Table 4 Relative cell number at different concentrations of compound (I)
[0238]
[0239] As shown in Table 5, it was confirmed that compound (I) has a superior nerve growth stimulating effect compared with compound A.
[0240] Table 5
[0241]
Claims
1. A crystalline form of 3-(15-methoxypentadecanyl)-2,4,4-trimethylcyclohex-2-ene-1-one, which has at least three peaks at diffraction angles (2θ±0.2°) selected from 7.0°, 14.0°, 17.5°, 19.5°, 21.0°, 23.7° and 24.8° in a powder X-ray diffraction pattern (CuKα).
2. The crystalline form according to claim 1, wherein the crystalline form has peaks at diffraction angles (2θ±0.2°) of 7.0°, 14.0°, 17.5°, 19.5°, 21.0°, 23.7° and 24.8° in a powder X-ray diffraction pattern (CuKα).
3. The crystalline form according to claim 1 or 2, wherein the powder X-ray diffraction pattern is substantially the same as the pattern shown in Figure 1.
4. The crystalline form according to any one of claims 1 to 3, wherein the crystalline form has an endothermic peak with a peak temperature of about 35°C in differential scanning calorimetry (DSC measurement).
5. A pharmaceutical composition comprising the crystal form according to any one of claims 1 to 4.
